OncLive TV

A rare cutaneous lymphoma that can mimic lupus and melt away on steroids still belongs in the malignancy category, based on how it behaves off treatment.

In part 2, the debaters map the trial that could settle the question and agree that, for now, individualized care and closer monitoring should guide high-risk early MF.

Stopping mogamulizumab after a strong response — then resuming it at relapse — emerged as a viable strategy for select patients with Sézary syndrome.

In the beginning of a two-part debate, two experts agree the evidence to treat poor-prognosis early MF differently from the onset isn’t here yet.

A planned mogamulizumab break emerged as best suited to older patients not bound for transplant, pending prospective confirmation.

Alicia Morgans, MD, MPH, discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial.

Alicia Morgans, MD, MPH, discusses the background of the ARACOG trial in prostate cancer.

Sara M. Tolaney, MD, MPH, highlights the FDA approval of sacituzumab govitecan plus pembrolizumab for first-line TNBC management.

Claire Roddie, PhD, FRCPath, MBChB, MRCP, discusses outcomes with obe-cel by disease burden at screening/lymphodepletion in B-cell acute lymphoblastic leukemia.

Michael A. Postow, MD, discusses the current evidence gaps surrounding the management of irAEs in melanoma in the long term.

David O’Malley, MD, discusses how ADCs have redefined the treatment paradigm in platinum-resistant ovarian cancer.

Brian Myre, MD, discusses early data with SYNC-T SV-102 in advanced/metastatic castration-resistant prostate cancer.

Mazyar Shadman, MD, MPH, discusses data from the phase 1/1b BGB-11417-101 trial of sonrotoclax plus zanubrutinib in frontline CLL/SLL.

Michael A. Postow, MD, discusses the importance of multidisciplinary coordination following immune checkpoint inhibitor therapy completion for patients with melanoma.

Michael A. Postow, MD, discusses the significance of understanding how to identify late-onset irAEs and underlying comorbidities unrelated to treatment in melanoma.

Sara M. Tolaney, MD, MPH, discusses an analysis of depth of response in HER2-positive advanced/metastatic breast cancer treated with T-DXd plus pertuzumab.

Alessandra Tedeschi, MD, discusses data from a subgroup analysis of the phase 3 SEQUOIA trial in CLL/SLL.

Everett Meyer, MD, PhD, discusses the ongoing investigation of Orca-T with reduced-intensity conditioning in hematologic malignancies.

Toni Choueiri, MD, discusses the significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Daniel H. Ahn, DO, discusses research surrounding the combination of atebimetinib and modified gemcitabine and nab-paclitaxel (Abraxane) in pancreatic cancer.

Talha Munir, MBChB, PhD, discusses the implications of an MAIC comparing zanubrutinib and ibrutinib in treatment-naive CLL.

Benjamin Croll, MD, discusses the present and potential future standing of biomarkers in RCC.

R. Lor Randall, MD, FACS, discusses how tumor-informed ctDNA sequencing can identify osteosarcoma relapse months before radiographic detection.

Mark D. Tyson, II, MD, MPH, discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC.

Benjamin Croll, MD, discusses research focused on understanding response to systemic therapy in RCC.

Peter Voorhees, MD, discusses efficacy data for talquetamab plus daratumumab with or without pomalidomide from MonumenTAL-3.

Stephan Stilgenbauer, MD, discusses safety considerations for BGB-16673 and where its development is headed in chronic lymphocytic leukemia.

Branko Cuglievan, MD, discusses data for revumenib in the pediatric R/R KMT2AR-acute leukemias subgroup from AUGMENT-101.

Pavlos Msaouel, MD, PhD, discusses the rationale for examining panitumumab-based treatment in SMARCB1-deficient RMC.

Jennifer Marvin-Peek, MD, discusses data for azacitidine, venetoclax, and ivosidenib, in IDH1-mutated acute myeloid leukemia and their significance.